Chelsea Therapeutics International 8-K 2012
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 13, 2012
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code (704) 341-1516
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 8.01. Other Events.
On February 13, 2012, Chelsea Therapeutics International, Ltd. issued a press release announcing that its Chief Executive officer will review Chelseas New Drug Application to the U.S. Food and Drug Administration for NORTHERA (droxidopa) and provide an update on the upcoming FDA Advisory Committee meeting during the companys presentation at BIO CEO on February 13, 2012. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.